Homepage - Well Referenced

Latest Articles

Association of Wearable Device-Measured Vigorous Intermittent Lifestyle Physical Activity with Mortality

This prospective cohort study analyzed data from 25,241 non-exercising adults (mean age 61.8 years) in the UK Biobank to assess the impact of vigorous intermittent lifestyle physical activity (VILPA) on mortality. VILPA, characterized by brief bouts (1–2 minutes) of vigorous activity during daily life, was measured using wearable accelerometers. Over

June 26, 2025 No Comments

Can a bout of exercise harm the human heart?

This commentary discusses a study by Stewart et al. (2016) that examined the effects of acute endurance exercise on cardiac function in recreationally active men. Participants performed two cycling trials: 90 minutes at heavy intensity and 120 minutes at moderate intensity. Findings indicated transient reductions in left and right ventricular

June 26, 2025 No Comments

Compact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine

This 2024 study evaluated the accuracy of a compact, disposable pressure monitoring device (Compass™) used during partial REBOA procedures in a swine model. Four Yorkshire pigs underwent induced hemorrhagic shock followed by REBOA with the Compass™ transducer. Mean arterial pressures recorded by the device were compared to standard arterial line

June 26, 2025 No Comments

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

This 2022 extension of the STEP 1 trial assessed the effects of discontinuing semaglutide 2.4 mg weekly in adults with obesity. After 68 weeks of treatment, participants had lost an average of 17.3% of their body weight. One year post-withdrawal, they regained approximately two-thirds of this weight loss, resulting in

June 26, 2025 No Comments

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial

This 2024 secondary analysis of a randomized clinical trial examined the effects of exercise, GLP-1 receptor agonist (liraglutide) treatment, and their combination on bone health in adults with obesity. After an initial 8-week low-calorie diet, 195 participants were randomized into four groups: exercise alone, liraglutide alone, combination of both, or

June 26, 2025 No Comments

Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database

This 2025 study conducted a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) to identify drugs associated with noninfectious myocarditis. Analyzing data from 2004 to 2024, the researchers found 10,763 reports of noninfectious myocarditis. The top five drugs with the highest reporting odds ratios (RORs) were phendimetrazine tartrate

June 26, 2025 No Comments

Mannitol-Enhanced Delivery of Stem Cells and Their Growth Factors Across the Blood-Brain Barrier

This review explores the use of mannitol, an osmotic agent, to transiently disrupt the blood-brain barrier (BBB) and facilitate the delivery of stem cells and their associated growth factors into the central nervous system. The authors discuss preclinical studies demonstrating that mannitol-induced BBB opening enhances the entry of various stem

Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis

This systematic review and meta-analysis evaluated the safety and efficacy of mesenchymal stem cell (MSC) therapy in adults with acute myocardial infarction (AMI) and ischemic heart failure (IHF). Analyzing 23 clinical trials (11 on AMI and 12 on IHF), the study found that MSC therapy was not associated with acute

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study

This prospective Phase I/II study evaluated the long-term safety and efficacy of intravenous umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy combined with disease-modifying anti-rheumatic drugs (DMARDs) in 64 patients with rheumatoid arthritis (RA). Patients received 2 × 10⁷ UC-MSCs via intravenous infusion and were followed for up to 3 years.

Concise Review: Stem Cell Interventions for People With Cerebral Palsy: Systematic Review With Meta-Analysis

This systematic review and meta-analysis evaluated the efficacy and safety of stem cell therapies in individuals with cerebral palsy (CP). Analyzing five clinical trials encompassing 328 participants, the study examined various stem cell types, including olfactory ensheathing cells, neural stem cells, neural progenitors, and allogeneic umbilical cord blood cells. The

Serious Adverse Events of Cell Therapy for Respiratory Diseases: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis assessed the safety profile of cell-based therapies in respiratory diseases by analyzing 23 clinical studies involving 204 patients with conditions such as ARDS, COPD, IPF, PAH, and others. The findings indicated that both systemic infusions and bronchial instillations of mesenchymal stem/stromal or progenitor cells were

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Leber’s Hereditary Optic Neuropathy

This study reports on the SCOTS trial, which utilized autologous bone marrow-derived stem cells (BMSCs) to treat patients with Leber's Hereditary Optic Neuropathy (LHON). Treatment methods included retrobulbar, subtenon, intravitreal, intra-optic nerve, subretinal, and intravenous injections of BMSCs. Patients experienced visual acuity improvements, with gains up to 35 letters on

Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies

This Phase I/IIa clinical trial evaluated the safety and efficacy of subcutaneous injections of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in 34 adult patients with moderate-to-severe atopic dermatitis (AD). Participants were randomized to receive either a low dose (2.5 × 10⁷ cells) or a high dose (5.0 ×

Stem Cells and Anti-Aging Genes: Double-Edged Sword—Do the Same Job of Life Extension

This 2018 review explores the synergistic relationship between stem cells and anti-aging genes, particularly Klotho, in combating aging. It posits that stem cells, alongside anti-aging genes, form a protective mechanism against aging-related damage. The review emphasizes that while this combination can delay aging and extend lifespan, imbalances or deficiencies may

A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD

This Phase II, multicenter, randomized, double-blind, placebo-controlled trial evaluated the safety and preliminary efficacy of systemic administration of allogeneic mesenchymal stem cells (MSCs) in 62 patients with moderate to severe COPD. Participants received four monthly intravenous infusions of 100 million MSCs (Prochymal) or placebo and were followed for two years.